AGIO – agios pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/9
02:07 am
agio
Medium
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/7
07:18 am
agio
Medium
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]
11/5
09:11 am
agio
Medium
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
11/5
09:05 am
agio
Medium
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
11/1
11:06 pm
agio
Low
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/31/2024
06:30 am
agio
-6.9%
MISS
8/1/2024
06:31 am
agio
-3.3%
MISS
5/2/2024
07:00 am
agio
3.2%
BEAT
11/1
12:38 pm
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
1.8%
11/1
12:38 pm
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
1.8%
11/1
12:31 pm
Reiterates
Outperform
Outperform
RBC Capital
Low
1.8%
11/1
12:31 pm
Reiterates
Outperform
Outperform
RBC Capital
Low
1.8%
11/1
10:18 am
Maintains
Sector Outperform
Sector Outperform
Scotiabank
Low
1.3%
11/14
03:45 pm
agio
Low
Form SC 13G/A AGIOS PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
11/13
04:15 pm
agio
Medium
Form 4 AGIOS PHARMACEUTICALS, For: Nov 08 Filed by: Washburn Theodore James Jr.
11/12
04:10 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Nov 07 Filed by: Ballal Rahul D.
11/12
04:08 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Nov 07 Filed by: Burns James William
11/8
04:20 pm
agio
Low
Form 144 AGIOS PHARMACEUTICALS, Filed by: Ballal Rahul D.
Show more
Top News Gainers
1/13 Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13 8.7%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
Top News Decliners
5/1 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock. -13.0%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3